Our group had previously seen good responses in a small group of patients with V600E mutated gliomas, including a patient with PXA with the use of BRAF/MEKi (10, 11) which served as proof-of-concept to pursue this therapy. This evidence concerns the gene BRAF and central nervous system cancer.